Daewon Pharmaceutical Co., Ltd. (KRX: 003220)

South Korea flag South Korea · Delayed Price · Currency is KRW
14,180
+180 (1.29%)
Nov 15, 2024, 3:30 PM KST
-12.09%
Market Cap 305.43B
Revenue (ttm) 566.09B
Net Income (ttm) 14.69B
Shares Out 21.43M
EPS (ttm) 677.80
PE Ratio 21.02
Forward PE 7.67
Dividend 300.00 (2.12%)
Ex-Dividend Date n/a
Volume 60,969
Open 13,910
Previous Close 14,000
Day's Range 13,910 - 14,180
52-Week Range 13,910 - 20,700
Beta 0.42
Analysts n/a
Price Target n/a
Earnings Date Nov 13, 2024

About Daewon Pharmaceutical

Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company’s principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a t... [Read more]

Sector Healthcare
Founded 1958
Employees 1,260
Stock Exchange Korea Stock Exchange
Ticker Symbol 003220
Full Company Profile

Financial Performance

In 2023, Daewon Pharmaceutical's revenue was 526.95 billion, an increase of 10.04% compared to the previous year's 478.88 billion. Earnings were 23.92 billion, a decrease of -25.13%.

Financial Statements

News

There is no news available yet.